Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes

Toshihide Kawai, Izumi Takei, Yuko Oguma, Norimi Ohashi, Mikiya Tokui, Shuji Oguchi, Fuminori Katsukawa, Hiroshi Hirose, Akira Shimada, Kiyoaki Watanabe, Takao Saruta

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

We investigated the efficacy of additional administration of 400 mg troglitazone (+T), which became available as a treatment for type 2 diabetes following the demonstration of its ability to reduce insulin resistance, in combination with diet (D + T) or sulfonylurea (S + T) therapy. Body fat area as determined by computed tomographic (CT) scanning at the umbilical level, as well as several clinical and biochemical parameters of glycemic control and lipid metabolism, were compared before and after 3 months of additional treatment with troglitazone. The body mass index (BMI) tended to increase in both groups (22.7 ± 0.6 v 23.2 ± 0.6 kg/m2 in D + T, nonsignificant [NS]; 22.2 ± 0.5 v 22.3 ± 0.5 kg/m2 in S + T, NS), while it tended to decrease in the control group (only diet therapy, 23.6 ± 0.6 v 23.1 ± 0.8 kg/m2, NS). Mean blood pressure ([BP] 96 ± 3 v 89 ± 4 mm Hg, P < .05) decreased significantly in the D + T group. Changes in the glycemic and lipid profile and leptin did not reach statistical significance. The D + T group showed a significant decline in immunoreactive insulin ([IRI] 12.4 ± 1.2 v 8.0 ± 1.0 μU/ml, P < .05), reflecting markedly reduced insulin resistance, as well as a significant increase in plasma insulin-like growth factor-1 ([IGF-1] 175.7 ± 14.2 v 189.8 ± 12.6 ng/mL, P < .05). A slight weight gain was associated with a tendency for subcutaneous fat to increase, while visceral fat decreased in both troglitazone-treated groups. The decrease in the visceral to subcutaneous fat ratio (V/S ratio) was statistically significant in the D + T group (1.09 ± 0.11 v 0.94 ± 0.09, P < .05), while the V/S ratio in the control group did not change. A notable finding of this study is the difference in the response to troglitazone between subcutaneous and visceral adipose tissue. It is suggested that troglitazone may exert beneficial effects by reducing visceral fat.

Original languageEnglish
Pages (from-to)1102-1107
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume48
Issue number9
DOIs
Publication statusPublished - 1999

Fingerprint

troglitazone
Type 2 Diabetes Mellitus
Subcutaneous Fat
Fats
Intra-Abdominal Fat
Insulin Resistance
Diet Therapy
Therapeutics
Umbilicus
Control Groups
Somatomedins
Leptin
Lipid Metabolism
Weight Gain
Adipose Tissue
Body Mass Index
Insulin
Diet
Blood Pressure
Lipids

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. / Kawai, Toshihide; Takei, Izumi; Oguma, Yuko; Ohashi, Norimi; Tokui, Mikiya; Oguchi, Shuji; Katsukawa, Fuminori; Hirose, Hiroshi; Shimada, Akira; Watanabe, Kiyoaki; Saruta, Takao.

In: Metabolism: Clinical and Experimental, Vol. 48, No. 9, 1999, p. 1102-1107.

Research output: Contribution to journalArticle

Kawai, Toshihide ; Takei, Izumi ; Oguma, Yuko ; Ohashi, Norimi ; Tokui, Mikiya ; Oguchi, Shuji ; Katsukawa, Fuminori ; Hirose, Hiroshi ; Shimada, Akira ; Watanabe, Kiyoaki ; Saruta, Takao. / Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. In: Metabolism: Clinical and Experimental. 1999 ; Vol. 48, No. 9. pp. 1102-1107.
@article{15bbe332787249e5b6e22b075e87fc44,
title = "Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes",
abstract = "We investigated the efficacy of additional administration of 400 mg troglitazone (+T), which became available as a treatment for type 2 diabetes following the demonstration of its ability to reduce insulin resistance, in combination with diet (D + T) or sulfonylurea (S + T) therapy. Body fat area as determined by computed tomographic (CT) scanning at the umbilical level, as well as several clinical and biochemical parameters of glycemic control and lipid metabolism, were compared before and after 3 months of additional treatment with troglitazone. The body mass index (BMI) tended to increase in both groups (22.7 ± 0.6 v 23.2 ± 0.6 kg/m2 in D + T, nonsignificant [NS]; 22.2 ± 0.5 v 22.3 ± 0.5 kg/m2 in S + T, NS), while it tended to decrease in the control group (only diet therapy, 23.6 ± 0.6 v 23.1 ± 0.8 kg/m2, NS). Mean blood pressure ([BP] 96 ± 3 v 89 ± 4 mm Hg, P < .05) decreased significantly in the D + T group. Changes in the glycemic and lipid profile and leptin did not reach statistical significance. The D + T group showed a significant decline in immunoreactive insulin ([IRI] 12.4 ± 1.2 v 8.0 ± 1.0 μU/ml, P < .05), reflecting markedly reduced insulin resistance, as well as a significant increase in plasma insulin-like growth factor-1 ([IGF-1] 175.7 ± 14.2 v 189.8 ± 12.6 ng/mL, P < .05). A slight weight gain was associated with a tendency for subcutaneous fat to increase, while visceral fat decreased in both troglitazone-treated groups. The decrease in the visceral to subcutaneous fat ratio (V/S ratio) was statistically significant in the D + T group (1.09 ± 0.11 v 0.94 ± 0.09, P < .05), while the V/S ratio in the control group did not change. A notable finding of this study is the difference in the response to troglitazone between subcutaneous and visceral adipose tissue. It is suggested that troglitazone may exert beneficial effects by reducing visceral fat.",
author = "Toshihide Kawai and Izumi Takei and Yuko Oguma and Norimi Ohashi and Mikiya Tokui and Shuji Oguchi and Fuminori Katsukawa and Hiroshi Hirose and Akira Shimada and Kiyoaki Watanabe and Takao Saruta",
year = "1999",
doi = "10.1016/S0026-0495(99)90122-1",
language = "English",
volume = "48",
pages = "1102--1107",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes

AU - Kawai, Toshihide

AU - Takei, Izumi

AU - Oguma, Yuko

AU - Ohashi, Norimi

AU - Tokui, Mikiya

AU - Oguchi, Shuji

AU - Katsukawa, Fuminori

AU - Hirose, Hiroshi

AU - Shimada, Akira

AU - Watanabe, Kiyoaki

AU - Saruta, Takao

PY - 1999

Y1 - 1999

N2 - We investigated the efficacy of additional administration of 400 mg troglitazone (+T), which became available as a treatment for type 2 diabetes following the demonstration of its ability to reduce insulin resistance, in combination with diet (D + T) or sulfonylurea (S + T) therapy. Body fat area as determined by computed tomographic (CT) scanning at the umbilical level, as well as several clinical and biochemical parameters of glycemic control and lipid metabolism, were compared before and after 3 months of additional treatment with troglitazone. The body mass index (BMI) tended to increase in both groups (22.7 ± 0.6 v 23.2 ± 0.6 kg/m2 in D + T, nonsignificant [NS]; 22.2 ± 0.5 v 22.3 ± 0.5 kg/m2 in S + T, NS), while it tended to decrease in the control group (only diet therapy, 23.6 ± 0.6 v 23.1 ± 0.8 kg/m2, NS). Mean blood pressure ([BP] 96 ± 3 v 89 ± 4 mm Hg, P < .05) decreased significantly in the D + T group. Changes in the glycemic and lipid profile and leptin did not reach statistical significance. The D + T group showed a significant decline in immunoreactive insulin ([IRI] 12.4 ± 1.2 v 8.0 ± 1.0 μU/ml, P < .05), reflecting markedly reduced insulin resistance, as well as a significant increase in plasma insulin-like growth factor-1 ([IGF-1] 175.7 ± 14.2 v 189.8 ± 12.6 ng/mL, P < .05). A slight weight gain was associated with a tendency for subcutaneous fat to increase, while visceral fat decreased in both troglitazone-treated groups. The decrease in the visceral to subcutaneous fat ratio (V/S ratio) was statistically significant in the D + T group (1.09 ± 0.11 v 0.94 ± 0.09, P < .05), while the V/S ratio in the control group did not change. A notable finding of this study is the difference in the response to troglitazone between subcutaneous and visceral adipose tissue. It is suggested that troglitazone may exert beneficial effects by reducing visceral fat.

AB - We investigated the efficacy of additional administration of 400 mg troglitazone (+T), which became available as a treatment for type 2 diabetes following the demonstration of its ability to reduce insulin resistance, in combination with diet (D + T) or sulfonylurea (S + T) therapy. Body fat area as determined by computed tomographic (CT) scanning at the umbilical level, as well as several clinical and biochemical parameters of glycemic control and lipid metabolism, were compared before and after 3 months of additional treatment with troglitazone. The body mass index (BMI) tended to increase in both groups (22.7 ± 0.6 v 23.2 ± 0.6 kg/m2 in D + T, nonsignificant [NS]; 22.2 ± 0.5 v 22.3 ± 0.5 kg/m2 in S + T, NS), while it tended to decrease in the control group (only diet therapy, 23.6 ± 0.6 v 23.1 ± 0.8 kg/m2, NS). Mean blood pressure ([BP] 96 ± 3 v 89 ± 4 mm Hg, P < .05) decreased significantly in the D + T group. Changes in the glycemic and lipid profile and leptin did not reach statistical significance. The D + T group showed a significant decline in immunoreactive insulin ([IRI] 12.4 ± 1.2 v 8.0 ± 1.0 μU/ml, P < .05), reflecting markedly reduced insulin resistance, as well as a significant increase in plasma insulin-like growth factor-1 ([IGF-1] 175.7 ± 14.2 v 189.8 ± 12.6 ng/mL, P < .05). A slight weight gain was associated with a tendency for subcutaneous fat to increase, while visceral fat decreased in both troglitazone-treated groups. The decrease in the visceral to subcutaneous fat ratio (V/S ratio) was statistically significant in the D + T group (1.09 ± 0.11 v 0.94 ± 0.09, P < .05), while the V/S ratio in the control group did not change. A notable finding of this study is the difference in the response to troglitazone between subcutaneous and visceral adipose tissue. It is suggested that troglitazone may exert beneficial effects by reducing visceral fat.

UR - http://www.scopus.com/inward/record.url?scp=0000708629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000708629&partnerID=8YFLogxK

U2 - 10.1016/S0026-0495(99)90122-1

DO - 10.1016/S0026-0495(99)90122-1

M3 - Article

C2 - 10484048

AN - SCOPUS:0000708629

VL - 48

SP - 1102

EP - 1107

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -